China Drug Registration Proposal Requires Clinical Trials For Follow-On Biologics - Sidley Austin
This article was originally published in PharmAsia News
Executive Summary
China's State Food and Drug Administration would require clinical studies for follow-on biologics under draft drug registration regulations published in March, according to comments submitted to SFDA by the Beijing office of U.S.-based law firm Sidley Austin